Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Interest & Investment Income (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Interest & Investment Income for 15 consecutive years, with $59000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 26.25% to $59000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $141000.0, a 57.14% decrease, with the full-year FY2024 number at $273000.0, down 31.75% from a year prior.
  • Interest & Investment Income was $59000.0 for Q3 2025 at Plus Therapeutics, up from $27000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $120000.0 in Q2 2023 to a low of $1000.0 in Q1 2025.
  • A 5-year average of $53882.4 and a median of $54000.0 in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 860.0% in 2022, then crashed 98.61% in 2025.
  • Plus Therapeutics' Interest & Investment Income stood at $5000.0 in 2021, then soared by 1360.0% to $73000.0 in 2022, then surged by 50.68% to $110000.0 in 2023, then tumbled by 50.91% to $54000.0 in 2024, then grew by 9.26% to $59000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Interest & Investment Income are $59000.0 (Q3 2025), $27000.0 (Q2 2025), and $1000.0 (Q1 2025).